Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies …
How patient-centricity embeds value and stability in LTFU studies
Phase I-III randomized controlled trials alone are not generating enough data to extrapolate conclusions and theories about therapeutics to the global population. Not all drugs demonstrate the same efficacy in the real world as shown in the clinical trials. Because of this, we are seeing a rise in long-term follow-up …
Exploring metastatic breast cancer immunotherapies: Are ADCs and ICIs the answer?
Breast cancer is the most common malignancy in women and the second most common cancer worldwide.1 Rates of breast cancer are increasing in many parts of the world, reflecting its association with social and lifestyle factors related to economic development, as well as increases in life expectancy.2 Although the disease …
Cell and Gene Therapy Answers: Bioanalytical support for cell and gene therapy
Your source for answers to the complex challenges of cell and gene therapy development. We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp drug development, regarding bioanalytical support for cell and gene therapy modalities. He shared some of the current challenges in cell and gene therapy, …
Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry
A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to …
Rare Disease Day 2022: Supporting patients, celebrating advancements
February 28 is Rare Disease Day, a day dear to the hearts of many at Labcorp. The day is observed to raise awareness and give support to the more than 300 million people worldwide living with rare diseases, as well as their family members and caretakers. At the heart of …
Cell and gene therapy answers: Overcoming challenges for rare disease in pediatrics (part two)
Your source for answers to the complex challenges of cell and gene therapy development. Building on the topic of rare diseases in our earlier blog, Labcorp cell and gene therapy leadership shared their insights on strategies for overcoming key challenges in rare disease studies in pediatric populations along with their …
Cell and Gene Therapy Answers: Advancing treatments for pediatric patients with rare diseases
Your source for answers to the complex challenges of cell and gene therapy development. Labcorp’s cell and gene therapy scientific leaders shared their insights on the factors that make rare and pediatric diseases a good fit for cell and gene therapy, along with the key challenges and best practices in …
Technologies, tools and processes to support patient-centric oncology trials
There is a gap between the number of patients needed to participate in new cancer trials and the number who give consent to take part. Decentralized clinical trials (DCTs) are helping to address this gap by increasing the reach of clinical studies beyond conventional research sites. DCTs provide an opportunity …
Addressing Challenges with Ulcerative Colitis Clinical Study Recruitment
We understand the significant challenges sponsors face with patient recruitment in their ulcerative colitis (UC) clinical studies. While the prevalence of UC is relatively high (~0.2% in North America, Oceania and much of Europe – and rising in urbanized/industrialized countries in Africa, Asia and Latin America1), recruitment rates into clinical …